William Blair & Company
SAGE

William Blair & Company’s Sage Therapeutics SAGE Stock Holding History

William Blair & Company’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,888
Closed -$265K – 1790
2019
Q3 		$265K Sell
1,888
-150
-7% -$25.1K ﹤0.01% 1171
2019
Q2 		$373K Buy
2,038
+400
+24% +$68.3K ﹤0.01% 1078
2019
Q1 		$261K Buy
+1,638
New +$237K ﹤0.01% 1196

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

William Blair & Company's SAGE Position: Q4 2019 in Review

William Blair & Company sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 1,888 shares — an estimated $265K sold.

William Blair & Company first reported a position in SAGE in Q1 2019 and held it in 3 quarters. The position peaked at $373K in Q2 2019. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • William Blair & Company reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • William Blair & Company sold 1,888 Sage Therapeutics shares in Q4 2019, an estimated $265K.
  • William Blair & Company first reported a position in Sage Therapeutics in Q1 2019 and held it in 3 quarters.
  • William Blair & Company's Sage Therapeutics position peaked at $373K in Q2 2019.
  • 266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on William Blair & Company's 13F filing for Q4 2019, filed 13 Feb 2020.